Tetralogic Pharmaceu (TLOG) 0.29 $TLOG
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.44 (-0.07), HTM: 0.80 (-0.02), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 0.47 (-0.04), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development
PR Newswire - Mon Apr 18, 6:00AM CDT
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, welcomes James E. Goldschmidt, Ph.D. to lead its business development team. Dr. Goldschmidt is responsible for developing new partnerships and brings to the Company more than 25 years of biotechnology and pharmaceutical experience, including most recently at Macrophage Therapeutics, and prior thereto at ImmuneXcite, TetraLogic Pharmaceuticals, Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham. Dr. Goldschmidt is a graduate of Villanova University and holds a master's degree from Drexel University and a Ph.D. from Temple University School of Medicine.
JNJ: 117.01 (+0.01), CASI: 1.31 (-0.08), TLOG: 0.29 (-0.02)
Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
ACCESSWIRE - Fri Apr 15, 11:09AM CDT
MIAMI, FL / ACCESSWIRE / April 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. EBIO, EXXI, TLOG, and RMHB have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), TLOG: 0.29 (-0.02)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.40 (-0.09), TTNP: 6.43 (+0.34), MNKD: 1.01 (-0.02), TLOG: 0.29 (-0.02)
Insider Alert: Here's Why These Small Caps Could Be Ready To Bounceâ?¦
ACCESSWIRE - Wed Jan 13, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / UltimateStockAlerts.com is a NASDAQ & NYSE Only Stock Alerts Service focused on day trading, swing trading and long-term investing. Our newsletter subscribers have witnessed upside in excess of 600% with realized gains of 296% in 2015 from 32 alerts. Receive free trade alerts via email or text message (SMS) on your phone by texting message ULTIMATE to number 555-888. Today we are taking a look at four companies which we believe could provide investors with significant volatility in the near term.
TLOG: 0.29 (-0.02)
TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs
GlobeNewswire - Wed Jan 06, 3:11PM CST
Birinapant Shows No Activity in Randomized Phase 2 MDS Study
TLOG: 0.29 (-0.02)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H2 2015 - 21 Companies & 24 Drug Profiles
M2 - Thu Dec 03, 7:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/9fwsbh/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Seattle Genetics, Inc. - Soligenix, Inc. - Taiwan Liposome Company, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - A-dmDT390-bisFv - AFM-13 - alemtuzumab - AMP-224 - Angeloxin - bexarotene - brentuximab vedotin - carfilzomib - CIGB-128 - CPI-613 - CS-055 - DNA IL-12 - everolimus - IPH-4102 - mogamulizumab - NMIL-121 - quisinostat hydrochloride - resminostat - sapacitabine - selinexor - SGX-301 - SHP-141 - trifarotene - vinorelbine tartrate For more information visit http://www.researchandmarkets.com/research/9f...eous_tcell
TLOG: 0.29 (-0.02), JNJ: 117.01 (+0.01), CYCC: 5.95 (-0.14), SGEN: 40.38 (-0.63), ONCS: 1.67 (-0.11), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Mon Nov 09, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts discussing clinical data on birinapant will be presented at the 57 Annual American Society of Hematology meeting to be held in Orlando from December 5-8, 2015, one of which is to be an oral presentation.
TLOG: 0.29 (-0.02)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 04, 3:02PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
TLOG: 0.29 (-0.02)
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
GlobeNewswire - Mon Nov 02, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase 2 clinical trial of suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE) in approximately forty patients with alopecia areata.
TLOG: 0.29 (-0.02)
Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market
ACCESSWIRE - Wed Oct 07, 7:14AM CDT
NEW YORK, NY / ACCESSWIRE / October 7, 2015 / We profile four development stage companies with exciting prospects for future growth. In the report, we describe the companies, their products and provide recommendations on which have the better prospects to realize their growth potential.
CTRV: 0.99 (+0.07), TROV: 4.28 (-0.60), TLOG: 0.29 (-0.02), KERX: 5.93 (-0.12)
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Aug 05, 3:01PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the second quarter ended June 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
TLOG: 0.29 (-0.02)
TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit
GlobeNewswire - Wed Jul 29, 6:32AM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) today announced that the Company will present at the Jefferies 2015 Hepatitis B Summit on Thursday, August 6, 2015 at 1:45 p.m. Eastern Time at the Boston Harbor Hotel. J. Kevin Buchi, CEO, will provide an overview of the Company, the Hepatitis B program and its corporate activities.
TLOG: 0.29 (-0.02)
TetraLogic Provides Update on Hepatitis B Clinical Program
GlobeNewswire - Mon Jul 20, 3:02PM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today provided an update on the status of its hepatitis B virus (HBV) clinical program.
TLOG: 0.29 (-0.02)
Updates on MDS Clinical Program - Free Research Report on TetraLogic Pharmaceuticals Corporation
PR Newswire - Wed Jul 15, 8:10AM CDT
ACI Association has initiated research coverage on TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
TLOG: 0.29 (-0.02)
TetraLogic Announces Update on MDS Clinical Program
GlobeNewswire - Tue Jun 30, 3:01PM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced preliminary data from the ongoing Phase 2A study of birinapant in combination with azacitidine in first line higher risk myelodysplastic syndromes (MDS). The study is being conducted as a precursor to the ongoing randomized Phase 2B study.
TLOG: 0.29 (-0.02)
Tracking the Pulse of the Healthcare Sector: Complementary Research on Corbus, Vascular Biogenics, Alexza, TetraLogic and Cleveland BioLabs
PR Newswire - Mon May 18, 6:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRBP: 2.98 (+0.03), CBLI: 2.61 (+0.01), VBLT: 4.90 (+0.10), TLOG: 0.29 (-0.02), ALXA: 0.95 (unch)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.44 (-0.07), HTM: 0.80 (-0.02), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 0.47 (-0.04), LPTN: 0.16 (unch), TLOG: 0.29 (-0.02)
James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of Business Development
PR Newswire - Mon Apr 18, 6:00AM CDT
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, welcomes James E. Goldschmidt, Ph.D. to lead its business development team. Dr. Goldschmidt is responsible for developing new partnerships and brings to the Company more than 25 years of biotechnology and pharmaceutical experience, including most recently at Macrophage Therapeutics, and prior thereto at ImmuneXcite, TetraLogic Pharmaceuticals, Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham. Dr. Goldschmidt is a graduate of Villanova University and holds a master's degree from Drexel University and a Ph.D. from Temple University School of Medicine.
JNJ: 117.01 (+0.01), CASI: 1.31 (-0.08), TLOG: 0.29 (-0.02)
Top Penny Stocks: Four Small Cap Stocks You Should Be Watching On April 15th
ACCESSWIRE - Fri Apr 15, 11:09AM CDT
MIAMI, FL / ACCESSWIRE / April 15, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. EBIO, EXXI, TLOG, and RMHB have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
EXXI: 0.13 (-0.01), EBIO: 1.87 (+0.19), TLOG: 0.29 (-0.02)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.40 (-0.09), TTNP: 6.43 (+0.34), MNKD: 1.01 (-0.02), TLOG: 0.29 (-0.02)
Insider Alert: Here's Why These Small Caps Could Be Ready To Bounceâ?¦
ACCESSWIRE - Wed Jan 13, 8:45AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / UltimateStockAlerts.com is a NASDAQ & NYSE Only Stock Alerts Service focused on day trading, swing trading and long-term investing. Our newsletter subscribers have witnessed upside in excess of 600% with realized gains of 296% in 2015 from 32 alerts. Receive free trade alerts via email or text message (SMS) on your phone by texting message ULTIMATE to number 555-888. Today we are taking a look at four companies which we believe could provide investors with significant volatility in the near term.
TLOG: 0.29 (-0.02)
TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs
GlobeNewswire - Wed Jan 06, 3:11PM CST
Birinapant Shows No Activity in Randomized Phase 2 MDS Study
TLOG: 0.29 (-0.02)
Global Cutaneous T-Cell Lymphoma Therapeutics Pipeline Review, H2 2015 - 21 Companies & 24 Drug Profiles
M2 - Thu Dec 03, 7:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/9fwsbh/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - Affimed Therapeutics AG - Chipscreen Biosciences Ltd - Cornerstone Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - Galderma S.A. - Innate Pharma SA - Johnson & Johnson - Karyopharm Therapeutics, Inc. - Kyowa Hakko Kirin Co., Ltd. - MedImmune, LLC - Neumedicines Inc. - Novartis AG - OncoSec Medical Inc. - Onyx Pharmaceuticals, Inc. - Sanofi - Seattle Genetics, Inc. - Soligenix, Inc. - Taiwan Liposome Company, Ltd. - TetraLogic Pharmaceuticals Drug Profiles - A-dmDT390-bisFv - AFM-13 - alemtuzumab - AMP-224 - Angeloxin - bexarotene - brentuximab vedotin - carfilzomib - CIGB-128 - CPI-613 - CS-055 - DNA IL-12 - everolimus - IPH-4102 - mogamulizumab - NMIL-121 - quisinostat hydrochloride - resminostat - sapacitabine - selinexor - SGX-301 - SHP-141 - trifarotene - vinorelbine tartrate For more information visit http://www.researchandmarkets.com/research/9f...eous_tcell
TLOG: 0.29 (-0.02), JNJ: 117.01 (+0.01), CYCC: 5.95 (-0.14), SGEN: 40.38 (-0.63), ONCS: 1.67 (-0.11), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
TetraLogic Pharmaceuticals Announces Clinical Data on Birinapant to be Presented at the 57th Annual American Society of Hematology Annual Meeting
GlobeNewswire - Mon Nov 09, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts discussing clinical data on birinapant will be presented at the 57 Annual American Society of Hematology meeting to be held in Orlando from December 5-8, 2015, one of which is to be an oral presentation.
TLOG: 0.29 (-0.02)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 04, 3:02PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
TLOG: 0.29 (-0.02)
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
GlobeNewswire - Mon Nov 02, 6:00AM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase 2 clinical trial of suberohydroxamic acid (4-methoxycarbonyl) phenyl ester (SHAPE) in approximately forty patients with alopecia areata.
TLOG: 0.29 (-0.02)
Pharmaceutical Sector Due Diligence Report - Searching for Opportunities Among the Bruised Small Cap Market
ACCESSWIRE - Wed Oct 07, 7:14AM CDT
NEW YORK, NY / ACCESSWIRE / October 7, 2015 / We profile four development stage companies with exciting prospects for future growth. In the report, we describe the companies, their products and provide recommendations on which have the better prospects to realize their growth potential.
CTRV: 0.99 (+0.07), TROV: 4.28 (-0.60), TLOG: 0.29 (-0.02), KERX: 5.93 (-0.12)
TetraLogic Reports Second Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Aug 05, 3:01PM CDT
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the second quarter ended June 30, 2015. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
TLOG: 0.29 (-0.02)
TetraLogic to Present at the Jefferies 2015 Hepatitis B Summit
GlobeNewswire - Wed Jul 29, 6:32AM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) today announced that the Company will present at the Jefferies 2015 Hepatitis B Summit on Thursday, August 6, 2015 at 1:45 p.m. Eastern Time at the Boston Harbor Hotel. J. Kevin Buchi, CEO, will provide an overview of the Company, the Hepatitis B program and its corporate activities.
TLOG: 0.29 (-0.02)
TetraLogic Provides Update on Hepatitis B Clinical Program
GlobeNewswire - Mon Jul 20, 3:02PM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) a clinical-stage biopharmaceutical company focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today provided an update on the status of its hepatitis B virus (HBV) clinical program.
TLOG: 0.29 (-0.02)
Updates on MDS Clinical Program - Free Research Report on TetraLogic Pharmaceuticals Corporation
PR Newswire - Wed Jul 15, 8:10AM CDT
ACI Association has initiated research coverage on TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.
TLOG: 0.29 (-0.02)
TetraLogic Announces Update on MDS Clinical Program
GlobeNewswire - Tue Jun 30, 3:01PM CDT
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced preliminary data from the ongoing Phase 2A study of birinapant in combination with azacitidine in first line higher risk myelodysplastic syndromes (MDS). The study is being conducted as a precursor to the ongoing randomized Phase 2B study.
TLOG: 0.29 (-0.02)
Tracking the Pulse of the Healthcare Sector: Complementary Research on Corbus, Vascular Biogenics, Alexza, TetraLogic and Cleveland BioLabs
PR Newswire - Mon May 18, 6:50AM CDT
Editor Note: For more information about this release, please scroll to bottom.
CRBP: 2.98 (+0.03), CBLI: 2.61 (+0.01), VBLT: 4.90 (+0.10), TLOG: 0.29 (-0.02), ALXA: 0.95 (unch)
